Seponering på grund af kliniske eller laboratoriemæssige bivirkninger forekom mindre hyppigt for irbesartan/ hydrochlorthiazid- behandlede patienter end for placebo- behandlede patienter.
Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan/ hydrochlorothiazide-treated patients than for placebo-treated patients.